Veradigm INC 8-K filings

Veradigm Inc. disclosed a net cash position of approximately $95 million as of September 30, 2024, while undergoing a strategic review process.

Veradigm Inc. terminated its credit agreement to avoid a potential default due to delays in providing required financial statements.

Veradigm Inc. disclosed a net cash position of $122 million as of June 30, 2024, comprising $330 million in cash and cash equivalents and $208 million in funded debt.

Veradigm Inc. has entered into a Stockholder Agreement with Charles and Jessica Myers, granting Charles Myers a board observer position and subjecting the Myers Parties to certain standstill restrictions.

Veradigm is exploring strategic alternatives, including a potential sale or merger, while also appointing a new interim CEO and extending the term of its interim CFO.

Veradigm Inc. has amended its Stockholder Rights Agreement to revise the definition of 'Beneficial Owner', specifically regarding agreements related to acquiring or disposing of company securities.

Veradigm Inc. will be delisted from the Nasdaq Stock Market following a Form 25 filing by Nasdaq, but its shares will continue to trade on the OTC Expert Market.

Veradigm Inc. reports that no noteholders exercised their repurchase rights following the delisting of its common stock, and the company terminated its capped call arrangements, receiving approximately 912,000 shares of common stock.

Veradigm Inc. has entered into an amendment to its credit agreement, providing an additional relief period for furnishing financial statements and adjusting certain financial covenants.

Veradigm reaffirmed its 2023 financial estimates and provided initial 2024 guidance, projecting revenue between $620 million and $635 million and adjusted EBITDA between $104 million and $113 million, while navigating delisting from Nasdaq.

Veradigm Inc. will move to the OTC Expert Market after being delisted from the Nasdaq, with trading suspended on February 29, 2024.

Veradigm Inc. has received notice of delisting from Nasdaq due to non-compliance with listing rules, with trading suspension effective February 29, 2024.

Veradigm adopts a stockholder rights plan and announces the acquisition of ScienceIO, a healthcare AI platform, while facing potential delisting from Nasdaq due to delayed financial filings.

Veradigm Inc. has amended its 0.875% Convertible Senior Notes due 2027 indenture, providing noteholders with new repurchase rights and modifying conversion terms, while also amending related capped call transactions.

Veradigm Inc. has amended its credit agreement, reducing its revolving loan facility from $700 million to $400 million and adjusting other terms.